Compounded semaglutide vs brand name Wegovy: what is the real difference?

Short answer They contain the same active molecule (semaglutide) but they are very different in how they’re made, regulated, labeled and tested. Wegovy (Novo Nordisk) is an FDA‑approved, manufacturer‑produced, prefilled pen specifically studied and labeled for chronic weight management. Compounded semaglutide is made by a pharmacy from bulk ingredients and is not FDA‑approved as an equivalent product — quality, potency, sterility, formulation and devices can vary.

Key differences (practical implications)

• Regulatory status and oversight

  • Wegovy: FDA‑approved for weight loss; made under strict GMP by Novo Nordisk and covered by standardized labeling and safety data.
  • Compounded: Made under state pharmacy rules. It is not FDA‑approved as “Wegovy.” FDA allows some compounding but does not vouch for equivalence or same safety/efficacy.

• Manufacturing quality, purity and potency

  • Wegovy: consistent potency, validated stability, and sterility of the prefilled pen.
  • Compounded: variability can occur (different excipients, concentrations, or impurities). Some pharmacies use bulk API that may lack appropriate testing. Risk of incorrect concentration or contamination is higher.

• Formulation and delivery device

  • Wegovy: comes in prefilled, dose‑accurate pens and a documented titration schedule; less room for dosing errors.
  • Compounded: may be supplied in vials or syringes or custom pens; dosing calculations may be required and increase risk of dosing errors or contamination.

• Evidence and labeling

  • Wegovy: large randomized clinical trials support its approved dose (2.4 mg weekly) and safety/education materials exist.
  • Compounded: no clinical trials proving that a compounded formulation is equivalent for weight‑loss indication.

• Safety monitoring and adverse event reporting

  • Wegovy: adverse events are tracked and reported back to the manufacturer/FDA.
  • Compounded: adverse events may be harder to trace to a specific batch or ingredient source.

• Cost and access

  • Wegovy can be expensive and may not be covered by insurance for everyone.
  • Compounded versions are often cheaper and used to increase access — but the cost savings come with the quality/safety tradeoffs above.

What to ask / check if you’re considering compounded semaglutide

• Is the pharmacy PCAB‑accredited (Pharmacy Compounding Accreditation Board)? Accreditation indicates adherence to higher standards.
• Can they provide a Certificate of Analysis (COA) showing identity, potency and purity of the bulk semaglutide API?
• Do they follow USP <797>/<800> sterile compounding standards and perform sterility/endotoxin testing?
• How is it packaged (single‑use prefilled pens vs multi‑dose vials)? What instructions/needle/device are provided?
• What stability data and refrigerator/storage instructions do they provide? Ask about beyond‑use dating.
• Will your prescriber document careful monitoring and titration plan (matching the Wegovy schedule if that’s the goal)?

Recommendations

• If you want the best-validated safety/efficacy and dose accuracy for weight management: choose Wegovy (Novo Nordisk) when possible.
• If cost or availability makes Wegovy impractical and you consider compounded semaglutide: use a reputable, PCAB‑accredited compounding pharmacy, insist on COA and sterility testing, and have your prescriber closely supervise dosing and monitoring.

Brands/services by name (to consider)

• Wegovy (Novo Nordisk): FDA‑approved product with standardized pens, labeled dosing, and large obesity trials — the safest/most reliable choice for weight loss.
• Ozempic (Novo Nordisk): semaglutide formulation approved for type 2 diabetes (different dosing); sometimes used off‑label for weight loss but not the same labeled product as Wegovy.
• For compounding pharmacies: look for a PCAB‑accredited, state‑licensed compounding pharmacy (search the PCAB registry) rather than ordering from an unknown online source. Ask that pharmacy for COAs and evidence of USP sterile compounding compliance.

Bottom line The active drug can be the same, but Wegovy is a regulated, tested, pen‑based product with proven dosing and safety for obesity. Compounded semaglutide may be cheaper or more available but carries more uncertainty about potency, sterility and equivalence. Discuss risks, benefits and monitoring with your prescriber before choosing a compounded product.